PLUS1
1.5801
0.1401 (9.73%)
0.1401 (9.73%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data! |
|
CHART Trader
Monthly Subscription
for only
|
|
Canadian Level 1 + USA
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Seelos Therapeutics Inc | SEEL | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded  |
|
|---|---|---|---|---|
| 0.1401 | 9.73% | 1.5801 | 19:59:34 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 1.51 | 1.37 | 1.62 | 1.61 | 1.44 |
| Bid Price | Ask Price | Spread | News | |
|---|---|---|---|---|
| 1.58 | 1.61 | 0.03 | 1 | 1 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 3,716 | 1,962,156 | $ 1.51 | $ 2,966,521 | 2,086,786 | 0.4195 - 2.09 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 19:58:34 | 80 | $ 1.62 | USD |
Seelos Therapeutics Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 85.96M | 54.40M | 51.18M | $ 375.00k | $ - | -4.47 | -2.80 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | - |
Seelos Therapeutics News
| Date | Time | Source | News Article |
|---|---|---|---|
| 1/15/2021 | 16:12 | Edgar (US Regulatory) | Amended Statement of Ownership (sc 13g/a) |
| 1/15/2021 | 08:30 | PR Newswire (US) | Seelos Therapeutics Announces Dosing of the First Patients.. |
| 1/12/2021 | 06:04 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 1/08/2021 | 16:31 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 1/08/2021 | 16:31 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 1/08/2021 | 16:30 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 1/06/2021 | 08:45 | PR Newswire (US) | Seelos Therapeutics Announces Year End 2020 Business Update |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical SEEL Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.43 | 1.62 | 1.36 | 1.45 | 764,189 | 0.1501 | 10.5% |
| 1 Month | 1.49 | 2.09 | 1.30 | 1.62 | 1,703,686 | 0.0901 | 6.05% |
| 3 Months | 0.801 | 2.09 | 0.722 | 1.31 | 1,390,954 | 0.7791 | 97.27% |
| 6 Months | 1.01 | 2.09 | 0.559 | 1.08 | 1,433,538 | 0.5701 | 56.45% |
| 1 Year | 1.46 | 2.09 | 0.4195 | 1.02 | 1,286,770 | 0.1201 | 8.23% |
| 3 Years | 4.02 | 8.00 | 0.4195 | 1.94 | 1,406,627 | -2.44 | -60.69% |
| 5 Years | 4.02 | 8.00 | 0.4195 | 1.94 | 1,406,627 | -2.44 | -60.69% |
Seelos Therapeutics Description
| Seelos Therapeutics Inc is engaged in the pharmaceutical industry. The company's pipeline products include SLS-002 which is intranasal racemic ketamine for patients with suicidality in post-traumatic stress disorder and depressive disorder; SLS-006 which is a small molecule, partial dopamine agonist for Parkinson's Disease; and SLS-005 is Trehalose, a protein stabilizer. Its other pipeline products include SLS-007, SLS-008, SLS-004, SLS-010, and SLS-012. |
